- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Sa | Amgen: A Biotech Giant's Path to Recovery and Growth | 32 | The Motley Fool | ||
| Do | AMGEN INC - Stabilität als Ausgangspunkt | 11 | Maximilian Berger | ||
| Mi | EQS-News: Amgen: Europäische Kommission erteilt Zulassung für Imdylltra von Amgen für die Behandlung von kleinzelligem Lungenkrebs im fortgeschrittenen Stadium | 768 | EQS Group (DE) | EQS-News: Amgen
/ Schlagwort(e): Sonstiges/Sonstiges
EUROPÄISCHE KOMMISSION ERTEILT ZULASSUNG FÜR IMDYLLTRA VON AMGEN FÜR DIE BEHANDLUNG VON KLEINZELLIGEM... ► Artikel lesen | |
| 02.06. | Amgen wins EU approval for Imdylltra in small cell lung cancer | 17 | Seeking Alpha | ||
| 02.06. | Amgen Secures EU Nod for Imdylltra in Lung Cancer Indication | 7 | Zacks | ||
| AMGEN INC CDR Aktie jetzt für 0€ handeln | |||||
| 01.06. | EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER | 530 | PR Newswire | Approval Based Upon Phase 3 DeLLphi-304 Trial Demonstrating 40% Reduction in Risk of Death with IMDYLLTRA Compared to Chemotherapy Novel Treatment Option for Patients with Extensive-Stage... ► Artikel lesen | |
| 31.05. | Amgen Stock: Is AMGN Outperforming the Healthcare Sector? | 23 | Barchart.com | ||
| 28.05. | Ember LifeSciences: $27 Million Series A Boosted By Amgen Ventures And TDF Ventures | 4 | pulse2.com | ||
| 26.05. | AMGN Stock Down 13% in 3 Months: Buy the Dip or Book Profits? | 18 | Zacks | ||
| 22.05. | Endokrine Orbitopathie: Amgen lenkt den Blick auf Versorgungslücken und gesellschaftliche Folgen | 500 | news aktuell | München (ots) - Bis zu zwei Jahre Diagnose-Wartezeit und Beeinträchtigung von Lebensqualität, Beruf und sozialer Teilhabe[1-4]Zum Weltschilddrüsentag am 25. Mai 2026 rückt das Biotechnologieunternehmen... ► Artikel lesen | |
| 21.05. | Amgen's Tavneos, facing liver injury scrutiny, gets label update in Japan as patient starts resume | 5 | FiercePharma | ||
| 21.05. | Amgen Inc. (AMGN): Navellier's Long-Term Pick on Pipeline Strength and Sales Growth | 6 | Insider Monkey | ||
| 20.05. | Amgen CFO Transition as Peter Griffith Retires, Thomas Dittrich Returns | 6 | Contract Pharma | ||
| 20.05. | Amgen, bidding adieu to CFO, lures Galderma exec with hefty $12.4M bonus | 4 | FiercePharma | ||
| 19.05. | Amgen announces CFO transition | 4 | Seeking Alpha | ||
| 19.05. | AMGEN INC - 8-K, Current Report | 2 | SEC Filings | ||
| 19.05. | Amgen Announces Retirement Of Chief Financial Officer Peter Griffith | 323 | PR Newswire | Thomas Dittrich Returning to Amgen as CFO
THOUSAND OAKS, Calif., May 19, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the retirement of Peter Griffith... ► Artikel lesen | |
| 18.05. | Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drug | 12 | BioPharma Dive | ||
| 18.05. | Amgen Japanese Partner Urges Caution On Tavneos Use | 7 | Benzinga.com | ||
| 16.05. | Amgen's Tavneos reportedly linked to 20 deaths in Japan | 27 | Seeking Alpha |
1 2 3 4 5 Weiter >>
311 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TANGO THERAPEUTICS | 30,940 | +0,03 % | Tango Therapeutics stock soars on promising pancreatic cancer data | ||
| NURIX THERAPEUTICS | 15,640 | 0,00 % | Biotech-Partnerschaft: Roche greift zu: Dieser Milliarden-Deal lässt Anleger aufhorchen | © Foto: Vladimir Borovic - Adobe StockRoche steigt mit einem milliardenschweren Deal bei Nurix ein. Im Fokus steht ein vielversprechender Wirkstoff gegen Krebs, Autoimmun- und Nervenkrankheiten.Der... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,110 | 0,00 % | All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy | ||
| COGENT BIOSCIENCES | 31,160 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) ... | Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 82,94 | -0,08 % | RBC Capital raises Apogee Therapeutics stock price target to $97 | ||
| PRAXIS PRECISION MEDICINES | 253,12 | -0,05 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ERASCA | 12,870 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,780 | 0,00 % | Beam Therapeutics Inc. - 8-K, Current Report | ||
| AMYLYX PHARMACEUTICALS | 13,010 | 0,00 % | H.C. Wainwright reiterates Amylyx stock rating on PBH trial insights | ||
| KINIKSA PHARMACEUTICALS | 49,040 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $930 - $945 million -- KPL-387... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 22,500 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 17,000 | 0,00 % | Pictet closes $1.53bn Monte Rosa Co-Investments VI fund, exceeding target | ||
| DYNE THERAPEUTICS | 16,820 | +0,06 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1) | - Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 - WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage... ► Artikel lesen | |
| CG ONCOLOGY | 54,36 | -0,07 % | CG Oncology, Inc. - 8-K, Current Report | ||
| RELAY THERAPEUTICS | 13,660 | 0,00 % | Relay Therapeutics Shares Jump 18% |
AMGEN INC CDR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 15,900 Euro und damit -1,85 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AMGEN INC CDR finden Sie auf Wallstreet Online.